Hypoxia induces chemoresistance of esophageal cancer cells to cisplatin through regulating the lncRNA-EMS/miR-758-3p/WTAP axis.
Animals
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
Cell Cycle Proteins
/ genetics
Cell Line, Tumor
Cisplatin
/ pharmacology
Drug Resistance, Neoplasm
/ genetics
Esophageal Neoplasms
/ drug therapy
Female
Gene Knockdown Techniques
Humans
Hypoxia
/ complications
Mice
Mice, Nude
MicroRNAs
/ genetics
Predictive Value of Tests
RNA Splicing Factors
/ genetics
RNA, Long Noncoding
/ genetics
Survival Analysis
Xenograft Model Antitumor Assays
EMS
chemoresistance
esophageal cancer
hypoxia
miR-758-3p
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
03 06 2021
03 06 2021
Historique:
received:
18
11
2020
accepted:
14
03
2021
pubmed:
4
6
2021
medline:
3
8
2021
entrez:
3
6
2021
Statut:
ppublish
Résumé
Hypoxia contributes significantly to the development of chemoresistance of many malignancies including esophageal cancer (EC). Accumulating studies have indicated that long non-coding RNAs play important roles in chemotherapy resistance. Here, we identified a novel lncRNA-EMS/miR-758-3p/WTAP axis that was involved in hypoxia-mediated chemoresistance to cisplatin in human EC. Hypoxia induced the expressions of lncRNA EMS and WTAP, and reduced the expression of miR-758-3p in EC cell line ECA-109. In addition, the expressions of EMS and WTAP were required for the hypoxia-induced drug resistance to cisplatin in EC cells, while overexpression of miR-758-3p reversed such chemoresistance. The targeting relationships between EMS and miR-758-3p, as well as miR-758-3p and WTAP, were verified by luciferase-based reporter assays and multiple quantitative assays after gene overexpression/knockdown. Moreover, we found significant correlations between tumor expressions of these molecules. Notably, higher levels of EMS/WTAP, or lower levels of miR-758-3p in tumors predicted worse survivals of EC patients. Furthermore, in a xenograft mouse model, targeted knockdown of EMS and WTAP in ECA-109 cells markedly attenuated the resistance of tumors to cisplatin treatments. Our study uncovers a critical lncRNA-EMS/miR-758-3p/WTAP axis in regulating hypoxia-mediated drug resistance to cisplatin in EC.
Identifiants
pubmed: 34081626
pii: 203062
doi: 10.18632/aging.203062
pmc: PMC8312407
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Cell Cycle Proteins
0
MIRN758 microRNA, human
0
MicroRNAs
0
RNA Splicing Factors
0
RNA, Long Noncoding
0
WTAP protein, human
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17155-17176Références
Nat Rev Mol Cell Biol. 2013 Nov;14(11):699-712
pubmed: 24105322
Mol Clin Oncol. 2017 May;6(5):743-747
pubmed: 28515926
Pharmazie. 2019 Apr 1;74(4):235-238
pubmed: 30940308
Adv Exp Med Biol. 2019;1136:123-139
pubmed: 31201721
Asian Pac J Cancer Prev. 2011;12(10):2461-6
pubmed: 22320939
Cancer Biol Med. 2017 Feb;14(1):33-41
pubmed: 28443201
Exp Ther Med. 2019 May;17(5):4273-4278
pubmed: 30988799
J Cancer Sci Ther. 2019;11(4):
pubmed: 32148661
Onco Targets Ther. 2019 Aug 06;12:6191-6201
pubmed: 31496724
J Cell Biochem. 2019 Feb 12;:
pubmed: 30756410
N Engl J Med. 2003 Dec 4;349(23):2241-52
pubmed: 14657432
Sci Rep. 2017 Nov 21;7(1):15929
pubmed: 29162879
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncogene. 2010 Feb 4;29(5):625-34
pubmed: 19946328
Tumour Biol. 2017 Jul;39(7):1010428317717983
pubmed: 28671053
J Biol Chem. 2004 Jun 4;279(23):24218-25
pubmed: 15044468
Oncol Lett. 2018 Dec;16(6):6966-6970
pubmed: 30546429
Mol Cancer Ther. 2008 Jul;7(7):1961-73
pubmed: 18645006
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
J Cell Physiol. 2019 Jul;234(7):10800-10808
pubmed: 30537154
J Cell Biochem. 2020 Feb;121(2):1023-1031
pubmed: 31452272
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Br J Cancer. 2003 Sep 15;89(6):1042-7
pubmed: 12966423
Int J Mol Sci. 2018 Feb 07;19(2):
pubmed: 29414899
Ann Transl Med. 2015 Dec;3(21):332
pubmed: 26734642
Cancer Cell. 2007 Aug;12(2):108-13
pubmed: 17692803
Cancer Res. 2002 Jun 15;62(12):3387-94
pubmed: 12067980
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818816061
pubmed: 30486755
Cell Death Differ. 2017 Jul;24(7):1263-1274
pubmed: 28498363
Gastroenterology. 2015 Dec;149(7):1700-15
pubmed: 26376349
Sci Rep. 2015 Jul 23;5:12291
pubmed: 26201611
J Hematol Oncol. 2018 Sep 17;11(1):118
pubmed: 30223861
J Exp Clin Cancer Res. 2018 Mar 12;37(1):56
pubmed: 29530057
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Cancer Res. 2012 Apr 1;72(7):1773-83
pubmed: 22447568
Anticancer Res. 2011 Jun;31(6):2351-9
pubmed: 21737664
RNA Biol. 2013 Jun;10(6):925-33
pubmed: 23696037
Mol Cancer. 2019 Aug 22;18(1):127
pubmed: 31438961
Cell. 2009 Feb 20;136(4):629-41
pubmed: 19239885
Biomed Pharmacother. 2017 Dec;96:535-544
pubmed: 29032337
Mol Carcinog. 2016 Dec;55(12):2095-2105
pubmed: 26756568
Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14620-14629
pubmed: 31262817
Cancer Res. 2014 Feb 1;74(3):665-74
pubmed: 24336068
Oncol Lett. 2017 Apr;13(4):2531-2538
pubmed: 28454430
J Mol Neurosci. 2016 Oct;60(2):131-6
pubmed: 27370540
Cell. 2013 Mar 14;152(6):1298-307
pubmed: 23498938
Nat Genet. 2015 Mar;47(3):199-208
pubmed: 25599403
World J Gastroenterol. 2013 Sep 14;19(34):5598-606
pubmed: 24039351
Intern Med. 2002 Feb;41(2):79-83
pubmed: 11868612
Cancer Sci. 2005 Mar;96(3):176-82
pubmed: 15771621
Cancer Metastasis Rev. 2007 Jun;26(2):311-7
pubmed: 17404691
Biomed Pharmacother. 2018 Jul;103:94-100
pubmed: 29635134